<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02805504</url>
  </required_header>
  <id_info>
    <org_study_id>5160165</org_study_id>
    <nct_id>NCT02805504</nct_id>
  </id_info>
  <brief_title>Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures</brief_title>
  <official_title>Efficacy of the Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, randomized controlled study to determine the efficacy of liposomal bupivacaine
      given by local injection at all the wound sites in patients undergoing urologic surgeries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, randomized controlled study to determine the efficacy of liposomal bupivacaine
      given by local injection at all the wound sites in patients undergoing urologic surgeries.
      Subjects of prospective study will be randomly divided using electronic program into two
      groups:

      The first group will receive intraoperative local Liposomal Bupivacaine injection at the port
      placement site. The control group will receive will local Marcaine (bupivacaine HCl)
      injection

      Primary Outcome Measures:

        -  Total opioid consumption measured in intravenous morphine equivalents dose during the
           postoperative hospital Stay

        -  Postoperative pain assessment using visual Analog Pain Scores &amp; Brief Pain Inventory
           form.

        -  Length of Hospital Stay

        -  Time to First Opioid Use.

        -  Postoperative Constipation , paralytic ileus
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total opioid consumption</measure>
    <time_frame>Postoperative day1-3</time_frame>
    <description>Postoperative analgesic use will be measured in oral morphine equivalents dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative pain assessment</measure>
    <time_frame>Postoperative day1-3</time_frame>
    <description>Pain score (1-10) will be used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of Hospital Stay and readmission</measure>
    <time_frame>30 days postoperatively</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>30 days postoperatively</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Urinary Tract Diseases</condition>
  <arm_group>
    <arm_group_label>Exparel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive intraoperative local Liposomal Bupivacaine injection (Exparel) at the port placement site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Marcaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will receive will local bupivacaine HCl (Marcaine) injection at the port placement site.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exparel</intervention_name>
    <description>This group will receive intraoperative local Liposomal Bupivacaine injection at the surgical site.</description>
    <arm_group_label>Exparel</arm_group_label>
    <other_name>liposomal bupivacaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Marcaine</intervention_name>
    <description>This group will receive intraoperative Bupivacaine HCl injection at the surgical site.</description>
    <arm_group_label>Marcaine</arm_group_label>
    <other_name>Bupivacaine HCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing urologic surgery.

        Exclusion Criteria:

          -  Pregnant and/or nursing mothers.

          -  Allergy to bupivacaine.

          -  History of drug/alcohol abuse.

          -  Severe cardiovascular, hepatic, renal disease or neurological impairment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Keheila, MD</last_name>
    <role>Study Director</role>
    <affiliation>Loma Linda University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed Keheila, MD</last_name>
    <phone>909 558 4196</phone>
    <phone_ext>44196</phone_ext>
    <email>mkeheila@llu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Loma Linda Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92350</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Keheila</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Abdelsattar JM, Boughey JC, Fahy AS, Jakub JW, Farley DR, Hieken TJ, Degnim AC, Goede W, Mohan AT, Harmsen WS, Niesen AD, Tran NV, Bakri K, Jacobson SR, Lemaine V, Saint-Cyr M. Comparative Study of Liposomal Bupivacaine Versus Paravertebral Block for Pain Control Following Mastectomy with Immediate Tissue Expander Reconstruction. Ann Surg Oncol. 2016 Feb;23(2):465-70. doi: 10.1245/s10434-015-4833-4. Epub 2015 Aug 26.</citation>
    <PMID>26307232</PMID>
  </reference>
  <reference>
    <citation>Hutchins J, Delaney D, Vogel RI, Ghebre RG, Downs LS Jr, Carson L, Mullany S, Teoh D, Geller MA. Ultrasound guided subcostal transversus abdominis plane (TAP) infiltration with liposomal bupivacaine for patients undergoing robotic assisted hysterectomy: A prospective randomized controlled study. Gynecol Oncol. 2015 Sep;138(3):609-13. doi: 10.1016/j.ygyno.2015.06.008. Epub 2015 Jun 6.</citation>
    <PMID>26056753</PMID>
  </reference>
  <reference>
    <citation>White S, Vaughan C, Raiff D, Eward W, Bolognesi M. Impact of liposomal bupivacaine administration on postoperative pain in patients undergoing total knee replacement. Pharmacotherapy. 2015 May;35(5):477-81. doi: 10.1002/phar.1587. Epub 2015 May 4.</citation>
    <PMID>25940854</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2016</study_first_submitted>
  <study_first_submitted_qc>June 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2016</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loma Linda University</investigator_affiliation>
    <investigator_full_name>D. Duane Baldwin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Bupivacaine</keyword>
  <keyword>Minimally Invasive Surgical Procedures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Urologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

